References
- Adamowicz P, Zuba D, Sekuła K. Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int. 2013;233:320–327.
- Bluelight. Available at: http://www.bluelight.ru. . Accessed September 20, 2014.
- Choi H, Heo S, Kim E, Hwang BY, Lee C, Lee J. Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicol. 2013;31:86–92.
- Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose–response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology. 2002;164:61–70.
- Drugs Forum. Available at: http://www.drugs-forum.com. . Accessed September 20, 2014.
- The European Monitoring Centre for Drugs and Drug Addiction. 2013 Available at: https://ednd.emcdda.europa.eu. . Accessed September 20, 2014.
- Frost JM, Dart MJ, Tietje KR, et al. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010;53:295–315.
- Gomes FV, Del Bel EA, Guimarães FS. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:43–47.
- Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A. Gas and liquid chromatography–mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol. 2013;37:265–276.
- Gurney SMR, Scott KS, Kacinko SL, Presley BC, Logan BK. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:54–78. Available at: . http://forend-ex.southernforensic.org/uploads/references/Gurney_et_al-_Pharm_Tox_of_Synthetic_Cannabinoids.pdf. . Accessed September 20, 2014.
- Herkenham N, Lynn AB, Johnston MR. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563–583.
- Hermanns-Clausen M, Kneisel S, Hutter M, Szabo B, Auwärter V. Acute intoxication by synthetic cannabinoids—four case reports. Drug Test Anal. 2013;5:790–794.
- Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–544.
- Huestis MA, Barnes A, Smith ML. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. Clin Chem. 2005;51:2289–2295.
- Huffman JW, Dai D. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett. 1994;4:563–566.
- Huffman JW, Padgett LW. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem. 2005;12:1395–1411.
- Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol. 1974;8:172–177.
- Karschner EL, Schwope DM, Schwilke EW, et al. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012;125:313–319.
- Kavanagh P, Grigoryev A, Savchuk S, Mikhura I, Formanovsky A. UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal. 2013;5:683–692.
- Kiplinger GF, Manno JE. Dose–response relationships to cannabis in human subjects. Pharmacol Rev. 1971;23:339–347.
- Liao X, Wiedmann TS. Solubilization of cationic drugs in lung surfactant. Pharm Res. 2000;20:1858–1863.
- Musshoff F, Madea B, Kerenbach-Wighton G, et al. Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med. 2014;128:59–64.
- Papafotiou KJ, Carter JD, Stough C. The relationship between performance on the Standardised Field Sobriety Tests, driving performance and the level of delta-9 tetrahydrocannabinol (THC) in blood. Forensic Sci Int. 2005;155(2–3):172–178.
- Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. Alcoholism. 1988;12:268–276.
- Schaefer CF, Gunn CG, Dubowski KM. Dose-related heartrate, perceptual, and decisional changes in man following marijuana smoking. Percept Motor Skills. 1977;44:3–16.
- Schaefer N, Peters B, Bregel D, et al. A fatal case involving several synthetic cannabinoids. Toxichem Krimtech. 2013;80:248–251.
- Smoking Blend Reviews. Available at: http://www.smokingblen-dreviews.com/ur-144. . Accessed September 20, 2014.
- Talk Hyperreal. Available at: http://talk.hyperreal.info. . Accessed September 20, 2014.
- The Trip Report. UR-144 Review. Available at: http://the-tripre-port.com/site/tripreport/ur-144-trip-report. . Accessed September 20, 2014.
- Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393–411.
- Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y. URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int. 2013;227:21–32.
- U.S. Drug Enforcement Administration. Background information and evaluation of “three factor analysis” (factors 4, 5 and 6) for temporary scheduling. 2013. Available at: http://165.189.64.111/Documents/Board%20Services/Agenda%20Materials/Controlled%20Substanc-es/2013/20130425_agenda_SUA3.pdf. . Accessed September 20, 2014.
- Vardakou I, Pistos C, Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197:157–162.
- Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilisation in lung surfactant. J Control Release. 2000;65:43–47.
- Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effect of tetramethylcyclopropyl ketone indoles. Neuropharmacology. 2013;75:145–154.
- World Health Organization. UR-144 Critical-Review Report. 2014. Agenda item 4.8. Available at: http://www.who.int/medicines/areas/quality_safety/4_8_Review.pdf. . Accessed September 20, 2014.
- Yeakel JK, Logan BK. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol. 2013;37:547–551.
- Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology. 1982;76:245–250.